Domatinostat

Domatinostat is an orally bioavailable small molecule that acts as a selective inhibitor of class I histone deacetylases (HDACs), specifically HDAC isoenzymes 1, 2, and 3. It also inhibits lysine-specific demethylase 1 (LSD1). By inhibiting these epigenetic regulators, domatinostat leads to the accumulation of acetylated histones and altered gene expression in tumor cells. This results in anti-tumor effects through direct cytotoxicity against cancer stem cells and modulation of the tumor microenvironment to enhance immune recognition. Domatinostat has been investigated primarily for its potential in treating various cancers—both as monotherapy and in combination with immune checkpoint inhibitors—by increasing tumor immunogenicity and facilitating T cell infiltration into tumors[1][5][6][7][8].

Other names

(e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide2-propenamide, n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)-, (2e)